
Atea Pharmaceuticals, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral antiviral drug candidates, including treatments for hepatitis C and COVID-19, based on nucleotide and nucleoside prodrug technology.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Polsky BruceDirector | Sell | $72K | 18,252at $3.95 | Nov 18, 2026 |
| Polsky BruceDirector | Sell | $61K | 14,254at $4.27 | Nov 16, 2026 |
| Polsky BruceDirector | Sell | $35K | 8,720at $4.03 | Nov 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable AVIR activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.